HC Wainwright & Co. Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $7
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on NextCure (NASDAQ:NXTC) with a Buy rating and announces a price target of $7.
August 08, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NextCure has been initiated with a Buy rating by HC Wainwright & Co. with a price target of $7.
The initiation of coverage with a Buy rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for NextCure. The price target of $7 indicates the analyst's bullish outlook on the stock, which could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100